Uptake of prostate-specific membrane antigen-targeted ¹⁸F-DCFPyL in avascular necrosis of the femoral head

Dear Editor,

We read the case report titled “Uptake of prostate-specific membrane antigentargeted ¹⁸FDCFPyL in avascular necrosis of the femoral head” by Torga et al.,[1] with great interest in the October—December issue of World Journal of Nuclear Medicine. They published the case of prostate carcinoma patient who has avascular necrosis of hip by positron emission tomography (PET)-computed tomography with prostate-specific membrane antigen. In addition, they have reported that the lack of pathologic diagnosis is the main limitation of their article.

However, we know that magnetic resonance imaging (MRI) is the most important imaging modality and also a basal radiological imaging for the main avascular necrosis classifications (University of Pennsylvania, Ficat and Arlet).[2],[3] In addition, MRI is the most helpful imaging modality for suspicious bone metastatic lesions. Hence, we think that in future, while planning to assess the frequency with prostate-specific membrane antigen-targeted PET scans, MRI imaging should be used for confirmation of the bone lesions.

Conflict of Interest

There are no conflicts of interest.

Financial support and sponsorship

Nil.

• References

• 1 Torga G, Yin Y, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head. World J Nucl Med 2019;18:416-9.
• 2 Zalavras CG, Lieberman JR. Osteonecrosis of the femoral head: Evaluation and treatment. J Am Acad Orthop Surg 2014;22:455-64.
• 3 Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br 1995;77:34-41.

Publikationsverlauf

Eingereicht: 19. April 2020

Angenommen: 10. Mai 2020

Artikel online veröffentlicht:
19. April 2022